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Study on cystic fibrosis mortality in 5 counkies 
S. Ravi l ly 1, H.V. Olesen 2, H.B. Quinton ~, L. Viviani 4, B. Wiedemarm 5, E. Le Roux 16, 
A. Par ant 6, G. Bell is 6 
~Vbincre la Mucoviscidose, Paris, France, ~Aathus University Hospital, Aathus, 
Denmark, 3Dartmouth Medical School, Hanover; NH, USA, 41stituto di Statistica
Medica e Biometria, Milano, ItalN Slnstitut fi~r Medizinische Informatik utul 
Biometrie, Dresdetg Germany, %tstitut National des Etudes Ddmographiques, 
Paris, Fratwe 
Aims:  National CF registries provide important information for the CF community. 
ha 2CO3, INED and Vaincre la Mucoviscidose asked several countries running CF 
registries to analyse mortality data from their registry identically. 
Methods:  In addition to France (F), four countries agreed to participate: Germany 
(G), Denmark (D), Italy (I), and USA. Data collected included: age distribution of 
deceased patients and of the entire population for at least hree years. For each 
country, a period life table has been constructed from which several indicators l ike 
death probabilities and life expectancies atdifferent ages are calculated. 
Results: Modalit ies of inclusion in the registries vary as wel l  as capture rate ha each 
country. Nevertheless trends tend to be very similar as shown ha table: 
F G D I USA 
Y~ats of study 1999 2001 1999 2001 1999 2002 1999 2001 1999 2001 
Number of patpnts 3396 3 834 397 4 200 21 116 
Number of deaths 47 44 7 46 342 
M~t ality rate (%) 13,9 11,4 17,0 19,8 16,2 
Mean age at death (yrs) 23,7 29,6 25,0 29,8 26,2 
Life expectancy at bttth (yrs) 40,5 49,4 41,6 41,6 39,1 
Life expectancy at 20yts (yrs) 94,6 25,7 25,4 26,3 22,9 
Conclusions: This data acknowledges similar trends for mortality: mean age at 
death and life expectancy at birth or at 20 years. Data analysed identically illustrates 
that overall CF care in these countries provides comparable results ha terms of l ife 
expectancy. Comparisons between countries have to be analysed with st andardised 
mortality rates to el iminate ffect of differences in population structure. 
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Use of antibiotics at 8 Scandinavian CF cenkes 
H.V. Olesen 1, P.K. Knudsen 2, Scandinavian CF Study Consortium 
iAathus University Hospital, Aathus, De~unatl G 2UllevaI University Hospital, Oslo, 
Norway 
The antibiotic treatment policies of the 8 cystic fibrosis centres in Denmark  (Aarhus 
(A), Cop nhagen (C)), Norway (Bergen (B), Oslo (O)) and Sweden (Gothenburg 
(G), Lund (L), Stockholm (S), Uppsala (U)) and the actual use of antibiotics were 
reviewed during the Scandinavian Pseudomot~s prevalence study. 
Data: Questionnakes on policies from all 8 centres. Status of Ra. infection (none, 
intermittent and cbr onic) by common definition (serology and/or culture). Antibiotic 
data as days of oral, inhalation and intravenous antibiotics with/without action 
against Ra.. When mixed treatment, the most intensive was regislered (iv>bib>oral). 
Continuous treatment (oral or inhalation) and continuous macrolide treatment were 
registered separately. Results were analysed with chi square or K W H. 
Results: 10 14 day courses of i.v. antibiotics for cbronic Pa.  infection were 
recommended 3 monthly at C,O and B, on demand at G,L and U, and as a mix of 
these at S and A. On demand therapy resulted in significantly less antibiotic days 
than regular intervals (median 21 vs. 48 days/y; p< 0.CO1). Continuous inhalation 
therapy for chronic Ra was recommended at3 centers (C,O,A). 
Total use of anti Ra. antibiotics ( iv and inh) differed significantly between centers 
for chronical ly (median 80 days/y; range 39(G) 334(C), p<0.001), and 
intermittently infected patients (median 10; range 10(13) 117(C); p~).CO2). 
The 4 centers (G,C,S and U)  recommending macr olide treatment to all chronically 
infected had sign. more patients on macrolides (66.7%) than the 3 centers (B,L,O) 
recommending trial of macrolides (21.4%) (p <0.CO1 ). 
Conclusion: In spite of close geographical,  cultural  mad socioeconomic 
relationship, the antibiotic treatment varied greatly both within and between the 
Scandinavian countries. 
451 
Age at diagnosis in CF registries: which date to choose? 
H. Jansen, C. Sevens 
on behalf of the Belgian CF registry (BMR-RBM) 
The BMR RBM was created in 1998 and covered in 2003 around 80% (850 patients 
and a 63% increase over 6 years) of the expected CF population calculated with a 
cmrier frequency of abnormal CFFR of 1:25. The overall Belgian data compare 
wel l  with those of other CF registries working with the same method of manual 
follow up of as many patients as possible. However our series, whatever the items, 
are small: the impact of l imited variations is high but the data analysis can be more 
precise. The age at diagnosis was investigated according to the terms of the CFF 
consensus (Rosentein BJ  et al, J Pediatr 1998; 132:589 595) for the patients who 
were diagnosed in the period 1998 2CO2. Data were collected from 196 patients, 
18 (9%) with a diagnostic date based only on clinical hislory were subtracted 
(undated objective data available for 90%). The median age at diagnosis for 178 
patients was 8.9 months, min imum minus 3 months (antenatal) and maximum 51 
years. 55 .1% were diagnosed before the age of 1 year and 60% before 2. The age 
at diagnosis was related to the most frequent cl inical suggestions for diagnosis. 
Family history, neonatal screening (15% of all BMR RBM patients on personal 
cl inical initiative) mad ha some instances meconium ileus did not automatically ead 
to early consensus compatible diagnosis. 8/18 subtracted patients were considered 
clinically diagnosed in the first month of life, 16 were diagnosed before the age of 
2 years. The inclusion of these patients into the study had a positive effect on the 
results. It is known that precise dates are difficult to obtain in registry settings. Our 
experience shows that in cl inical CF epidemiology the criteria for age at diagnosis 
might be different from the clinically admitted rules in order to be a measurement 
of the quality of care. 
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Prevalence of Pseudomonas aeruginosa (PA) and segregaSon and 
bacteriological surveillance policies at 8 Scandinavian CF centres 
P.K. Knudsen 1, H.V. Olesen 2, A. Lindblad 3, Scandinavian CF Study Consortium 
iUllevaI University Hospital, Oslo, Norway, ~Aathus University Hospital, Aathus, 
Detunat*, SQueen Silvia ChiMren's Hospital, Gothenburg, Sweden 
Prevalence based on serological and clinical data from 979 patients ha the 
Scandinavian Pseudomonas prevalence study, mad policies based on questionnaires 
to the 8 cystic fibrosis centres ha Scandinavia re presented. 
Results: 
Denmark N 358 Norway N 199 Sweden N~.22 
Prevalence of chronic PA infection* (%) 43,3 34,3 43,8 
Median age (yem s) 16,3 17,9 16,8 
*Precipifins against PA >2 and/or PA cultured at least hree times the last 6 months 
No significant differences for median age. Prevalence significantly lower in 
Norway compared to Denmark (p~),044) and compared to Sweden (p 0,037) (Chi 
square with Yates' correction). 
Segregation policies: 
PA patients segregated from non PA in the out patient clinic in Denmark and 
Norway, but not in Sweden. 
In patients: Single rooms in all centres, except Copenhagen who practice cohort 
isolation. PA at special ward in Denmark. 
Bacteriological surveillance: 
Sputum producing patients: Cultures obtained at every outpat ient visit in all 
centres (every 4 6 week). 
Non sputum producing patients: There was a general tendency towards more 
frequent bacteriological cultures (nasopharyngeal swab and induced sputum in 
Sweden, laryngeal aspiration in Denmark  and Norway) in the Danish and 
Norwegian centres compared to he Swedish centres. 
Conclusion: Prevalence of cbr onic PA infection was significantly lower in Norway 
compared to Denmark and Sweden despite no differences in median age. PA 
prevalence related to possible differences in pancreatic and genetic status wi l l  be 
reviewed later. Despite different segregation policies ha Denmark and Sweden, there 
was no difference in prevalence of chronic PA between the two countries. 
